



Genomic Health, Inc.
Investor Relations Department
301 Penobscot Dr.
Redwood City, CA 94063
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: GHDX

| | |
|---------------|----------------------------|
| Last Trade: | 29.37 |
| Trade Time: | 4:00 PM ET May 23, 2017 |
| Change: | -0.22 (-0.743%) |
| Day Range | 29.23 - 29.70 |
| 52-Week Range | 24.81 - 33.96 |
| Volume | 100,166 |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- May 13, 2017*
[Prospective Oncotype DX® Genomic Prostate Score™ Test Data Presented at AUA and Published in Urology Establish Test's Ability to Increase Use and Persistence on Active Surveillance in Prostate Cancer Patients](#)
- May 12, 2017*
[Oncotype DX® Genomic Prostate Score™ \(GPS\) Test Predicts 10-year Risk of Prostate Cancer-specific Death and Metastases in Patients with Early-stage Disease](#)
- May 10, 2017*
[Genomic Health to Present at Bank of America Merrill Lynch 2017 Health Care Conference](#)
- May 9, 2017*
[Genomic Health Announces First Quarter 2017 Financial Results and Reports Recent Business Progress](#)
- May 4, 2017*
[Genomic Health Announces Favorable Draft Local Coverage Determination \(LCD\) on Medicare Coverage for Use of Oncotype DX® Genomic Prostate Score™ in Patients with Favorable Intermediate-risk Prostate Cancer](#)

Financials & Filings [\[View all \]](#)

- Mar 15, 2017*
[Annual Report \(10-K\)](#)
- Apr 28, 2017*
[Proxy Statement \(DEF 14A\)](#)
- May 10, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 4, 2016*
[Quarterly Report \(10-Q\)](#)
- Aug 9, 2016*
[Quarterly Report \(10-Q\)](#)

